# Himuka AM Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/himuka-am-pharma

- Industry: Biotechnology
- Headquarters: Miyazaki, Japan
- Website: https://www.himuka-am.com
- Total disclosed funding: $5.6M
- Latest round: Series B (Jan 14, 2022)
- Investors on record: 9

## About

Himuka AM Pharma Corp. is a biopharmaceutical company focused on the research and development of innovative therapeutics, specifically targeting advanced medical solutions through its HM201 product line.Himuka AM Pharma Corp. specializes in developing biopharmaceutical solutions and is headquartered in Miyazaki, Japan. The company was founded in 2017 and has completed a total of 5 deals, including Series B funding in January 2022, where it raised JPY 230 million from investors including Fiducia, Nanto Capital Partners, and Venture Labo Investment. The current company valuation stands at JPY 2,038.235 million. The CEO of the company is Hiroshi Shinjo, who has been instrumental in steering the company’s operational direction.Himuka AM Pharma Corp. focuses on the research and development of innovative therapeutics, with a particular emphasis on the HM201 product line. HM201 is designed to target specific medical indications, operating within the framework of advanced biopharmaceutical solutions. The company has successfully completed Phase 1 clinical trials for HM201 in Australia, marking a significant milestone in its product development timeline. The end-users of these products primarily include healthcare providers and patients in need of effective therapeutic interventions. Geographically, the company's offerings are targeted towards markets in Australia, Japan, and potentially other regions seeking advanced medical solutions.Himuka AM Pharma Corp. generates revenue through strategic financing and clinical trial programs, including partnerships and funding rounds such as the Series B financing. The company’s transactions involve agreements with healthcare institutions and research organizations, where funding is allocated for clinical trials and product development. This collaborative approach facilitates the advancement of HM201 and other pipeline products through systematic testing phases. While specific pricing structures for their products and services have not been disclosed, the firm’s focus on clinical research and development implies a revenue model predicated on successful trial outcomes and subsequent market introductions. The revenue framework may include partnerships with pharmaceutical distributors and healthcare providers, enhancing the accessibility and distribution of their therapeutics upon market release.In January 2022, Himuka AM Pharma Corp. raised JPY 230 million in Series B funding, which will contribute to ongoing clinical trials for new medicines. The company is focusing on advancing the HM201 product line and is exploring opportunities to expand its market presence into new regions, particularly targeting healthcare sectors in Australia and Japan. This strategic funding will facilitate the continued development of their innovative therapeutics, enhancing their pipeline products as they aim for successful market introduction.

## Funding rounds

- Series B, Jan 14, 2022, $2M — Venture Labo Investment, Fiducia, Nanto Capital Partners
- Series B, Aug 3, 2021, $3.6M — Mitsubishi UFJ Capital, KSP, Miyazaki Taiyo Capital, Miyagin Venture Capital, QB Capital, Beta Venture Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- KSP (https://capitalatlas.ai/funds/ksp) — Series B
- Miyazaki Taiyo Capital (https://capitalatlas.ai/funds/miyazaki-taiyo-capital) — Series B
- Miyagin Venture Capital (https://capitalatlas.ai/funds/miyagin-venture-capital) — Series B
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series B
- Beta Venture Capital (https://capitalatlas.ai/funds/beta-venture-capital) — Series B
- Venture Labo Investment (https://capitalatlas.ai/funds/venture-labo-investment) — Series B
- Fiducia (https://capitalatlas.ai/funds/fiducia) — Series B
- Nanto Capital Partners (https://capitalatlas.ai/funds/nanto-capital-partners) — Series B